News of Note—MaxiVAX, PATH and more
admin 17th July 2018 Uncategorised 0Here is some other vaccine news of note for the week. More: News of Note—MaxiVAX, PATH and more Source: fierce
read more
Here is some other vaccine news of note for the week. More: News of Note—MaxiVAX, PATH and more Source: fierce
read moreFollowing a layoff round affecting 107 employees, Bristol-Myers Squibb is cutting an additional 149 positions at its site in Wallingford, Connecticut, with the aim to completely close it by the end of this year. More: Bristol-Myers Squibb to lay off
read moreAfter negotiations ran aground—and tempers flared—earlier this month, England’s National Health Service has made its “final” offer to cover Vertex’s cystic fibrosis drugs. But the company still isn’t happy with the proposal. More: Vertex says it's glad England made another
read moreAmid an industrywide debate over drug prices, top player Johnson & Johnson reports its net prices will fall between 4% and 6% in 2018. More: Johnson & Johnson predicts 4% to 6% net price decline in pharma this year, with
read morePfizer is taking heat from Congress and Wall Street analysts alike—not for bowing to President Donald Trump’s pressure to hold off on price increases, but for the tepid nature of its promises. More: Winning Trump’s praise was easy for Pfizer.
read moreRoche says its investigational flu drug baloxavir marboxil, in-licensed from Japan’s Shionogi, has met key goals in a late-stage trial. More: Roche’s antiviral hits flu targets in PhIII trial Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals